The Flow Cytometry Unit provides extensive support for NCI clinical protocols by providing diagnostic testing for leukemia and lymphoma in patients either on NCI clinical protocols or undergoing testing to determine eligibility for said protocols. The Flow Cytometry Unit provides clinical flow cytometric evaluation of blood, bone marrow, fine needle aspirates, tissue biopsies and body fluids for hematolymphoid neoplasia in NCI and NIH patients. The majority of flow cytometric testing performed by the Flow Cytometry Unit involves detection of minimal residual disease (patients are status post therapy at outside institution prior to enrollment on NCI protocol) and measurement of specific tumor cell characteristics mandated by various clinical protocols. Significant effort in the unit is devoted to delivery of numerous unique protocol mandated assays that are not offered by commercial laboratories. The Flow Cytometry Unit is also actively engaged in education of the NIH staff and medical community at large in the proper utility of flow cytometry in medical practice.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Scientific Cores Intramural Research (ZIC)
Project #
1ZICSC009372-22
Application #
8763794
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
22
Fiscal Year
2013
Total Cost
$1,583,756
Indirect Cost
Name
National Cancer Institute Division of Clinical Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Stetler-Stevenson, Maryalice (2014) Monoclonal B-cell lymphocytosis in donors. Blood 123:1281-2
Tembhare, Prashant R; Yuan, Constance M; Venzon, David et al. (2014) Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leuk Res 38:371-6
Roschewski, Mark; Stetler-Stevenson, Maryalice; Yuan, Constance et al. (2014) Minimal residual disease: what are the minimum requirements? J Clin Oncol 32:475-6
Haso, Waleed; Lee, Daniel W; Shah, Nirali N et al. (2013) Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121:1165-74
Cherry, Benjamin M; Korde, Neha; Kwok, Mary et al. (2013) Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk Lymphoma 54:2215-8
Flanders, Aaron; Stetler-Stevenson, Maryalice; Landgren, Ola (2013) Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. Blood 122:1088-9
Shaffer, Brian C; Modric, Marko; Stetler-Stevenson, Maryalice et al. (2013) Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia. Exp Hematol 41:772-8
Klion, Amy D; Mejia, Rojelio; Cowen, Edward W et al. (2013) Chronic active Epstein-Barr virus infection: a novel cause of lymphocytic variant hypereosinophilic syndrome. Blood 121:2364-6
Manasanch, Elisabet E; Braylan, Raul; Stetler-Stevenson, Maryalice et al. (2013) Lack of MYD88 L265P in non-IgM lymphoplasmacytic lymphoma. Leuk Lymphoma :
Shao, Haipeng; Calvo, Katherine R; Gronborg, Marlene et al. (2013) Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. Leuk Res 37:401-9

Showing the most recent 10 out of 16 publications